Mésylate de déféroxamine - Výsledky vyhľadávania

Európska únia - slovenčina - EMA (European Medicines Agency)

masivet

ab science s.a. - masitinib mesilate - antineoplastické činidlá - psy - liečba neresetovateľných nádorov mastocytov u psov (stupeň 2 alebo 3) s potvrdeným mutovaným receptorom tyrozínkinázy c-kit.

Európska únia - slovenčina - EMA (European Medicines Agency)

tagrisso

astrazeneca ab - osimertinib mesilate - karcinóm, pľúc bez malých buniek - iné antineoplastické činidlá, protein kinase inhibítory - tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations- the first-line treatment of adult patients nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc. tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations. - the first-line treatment of adult patients with locally advanced or metastatic nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc.

Európska únia - slovenčina - EMA (European Medicines Agency)

dabigatran etexilate accord

accord healthcare s.l.u. - dabigatran etexilate mesilate - venous thromboembolism; arthroplasty, replacement - antitrombotické činidlá - prevention of venous thromboembolic events.